In addition, the IHC CD8 + density analysis in the subset of tislelizumab-treated patients from NCT02407990 revealed a higher tumor and stromal CD8 + T cell abundance in TAP ≥ 5%, HA − versus TAP ≥ 5%, HA + subgroups (Supplementary Fig. 8). Here, CD8A is linked to neoplasm.